We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bristol-Myers Squibb Cancer Therapy Prolongs Melanoma Survival

Bristol-Myers Squibb Cancer Therapy Prolongs Melanoma Survival

June 25, 2014

Bristol-Myers Squibb stopped a Phase III trial of its cancer drug nivolumab early, after determining it was likely to prolong survival in advanced melanoma patients, the company said Tuesday.

The 418-patient study, dubbed CheckMate-066, tested nivolumab as an initial therapy for patients with advanced melanoma who couldn’t undergo surgery and had yet to be treated, the New York-based drugmaker said.

BMS said an independent data monitor analyzed the data from the blinded trial, which showed indication of superior overall survival in patients receiving nivolumab compared to the control arm, which received the chemotherapy dacarbazine. Dacarbazine patients were unblinded and allowed to switch to nivolumab, it added.

Nivolumab belongs to a new class of medicines called PD-1 inhibitors, which display the ability to help the immune system recognize and attack cancer.

The company said it is studying nivolumab against other tumor types in more than 35 trials—either alone or as part of a combo. These include trials in non-small cell lung cancer melanoma, renal cell carcinoma, head and neck cancer, glioblastoma and non-Hodgkin lymphoma.

An earlier Bristol-Myers nivolumab study discovered it shrank tumors in 28 percent of melanoma patients, 27 percent with kidney cancer and in 18 percent of people with advanced lung cancer, the drugmaker said.

Bristol-Myers didn’t say how much longer patients on nivolumab survived compared to those on dacarbazine.

Nivolumab received FDA Breakthrough Therapy Designation in May for the treatment of patients with Hodgkin lymphoma. — Kellen Owings

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.

Pharmaceuticals Research and Development

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing